Revenio Group Corporation
The answer first
Does Revenio Group beat the market?
No, Revenio Group has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 34% of Nordic stocks
- Quality68
- Value56
- Trend7
No. 94 of 195 in healthcare
Expectations in the price
Moderate expectations
For the share to return about 9% a year from today's price, the cash Revenio Group keeps must grow about 7% a year for 10 years.
Max for seven days
Follow Revenio Group with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Revenio Group
Your first answer is free, no account needed.
Do you own Revenio Group, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Revenio Group and a few more. Free, no card.
Super Stock+44.6%In short
- Revenio Group has fallen 58.1% over the past year, including dividends.
- Overall, Revenio Group ranks better than 34% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 74.4%. The price is 86.3% below its peak now.
What do analysts think of Revenio Group?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 34% of Nordic stocks.
No. 94 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 89 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.94
- Asset turnoverSales divided by everything the company owns0.33
- Return on equityProfit divided by equity+7.7%
- Cash conversionOperating cash flow divided by profit1.38
The ranking is built on equity ratio, ROA and how steadily profit grows.
Medium Fair price: about the same as a typical Nordic stock.
No. 39 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity1.7
- P/SPrice divided by sales1.7
- P/EPrice divided by earnings21.9
- P/CFPrice divided by operating cash flow15.8
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 166 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−36.9%
- 6 months−34.5%
- 9 months−49.6%
- 12 months−58.1%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Revenio Group
7 funds we follow own Revenio Group. The share is how much of the fund the stock makes up.
- Norway1
- Sweden6
- TIN Småbolag ASweden · TIN2.1%
- Case Gaia MicrocapSweden · Case2.0%
- Case All StarSweden · Case1.5%
- Protean Aktiesparfond Norden ASweden · Protean1.1%
- Kvartil Nordiska Småbolag+ Faktor ASweden · Kvartil0.2%
- Handelsbanken Norden Ind Crit (A1 NOK)Sweden · Handelsbanken0.1%
- KLP AksjeNorden IndeksNorway · KLP0.0%
From the funds' latest known holdings.
About Revenio Group
Revenio Group Corporation is a company in healthcare, listed on Nasdaq Helsinki. The share trades in EUR. It has around 760 employees.
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Sensors that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used by veterinarians, ophthalmologists and other personnel to measure intraocular pressure in animal patients.


See the full analysis of Revenio Group.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card